Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix Group PLC making progress on all fronts – Jefferies

Regenerative medtech Tissue Regenix Group PLC is making clear progress on all fronts, said heavyweight US broker Jefferies today, which rates the shares a 'buy'.
Tissue Regenix Group PLC making progress on all fronts – Jefferies
But Jefferies reckons the group's orthopedic products - OrthoPure - will provide the next leg of growth....

Regenerative medtech Tissue Regenix Group PLC (LON:TRX) is making clear progress on all fronts, said heavyweight US broker Jefferies today, which rates the shares a 'buy'.

The group is a wound care expert, with its Dermapure product being used to rebuild cells in the most difficult of wounds.

The broker noted that product (Dermapure ) has now surpassed the $1mln revenue mark and with nine of 11 medicare administrators secured (and promising private payor progress) analyst Chris Cooper expect further acceleration through full year 16/17, particularly now the "hybrid sales model is well established and senior sales directors are in place".

But Jefferies reckons the group's orthopedic products - OrthoPure -  will  provide the next leg of growth and will provide meaningful revenues from the first half of the 2017/18 year.

More than 1.5mln people suffer meniscal injuries in the US and EU alone, of which OrthoPure XM would likely target 300,000, it notes.

"The other key franchise in the orthopedics portfolio is OrthoPure XT (ACL repair), for which the trial commenced in Dec-15 with first results likely in 1H16/17. The company is on target to launch the human tissue orthopedic products in the US by end-FY16/17," added Cooper.

Also significant, the firm was granted last week US regulatory clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue, signalling a commercial launch in the US later this year.

"We estimate FY17 Dermapure/ Surgipure sales of $9m/$0.6m, with $2.9m from Orthopure by FY18. We continue to view orthopedics as the greater LT value driver and are encouraged by progress to date," concluded the analyst.

Jefferies raises the price target to 37p from 36p  - which is more than double the  current share price of 17.5p.

Giles_55af4ddca6481.jpg
Why Invest In Tissue Regenix Group PLC? Read More Here

Register here to be notified of future TRX Company articles
View full TRX profile

Tissue Regenix Group PLC Timeline

Related Articles

Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin
knee_5672a90cad559.jpg
December 17 2015
Put simply, Tissue Regenix takes a tendon or cartilage – either from a human or from a pig – treats it and uses it to replace damaged tissue within the body.
blood_56ceb82789b61.jpg
February 25 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.